CRISPR/Cas13-mediated Dynamin 2 reduction therapy in a canine model of DNM2-related centronuclear myopathy
Carlier, A.; Barthelemy, I.; Blanchard-Gutton, N.; Chateau-Joubert, S.; aurade, F.; Ozturk, T.; Didier, N.; Relaix, F.; Tiret, L.; Blot, S.; Punzon, I.
Show abstract
We determined the potential of CRISPR/Cas13 technology as a therapeutic approach for centronuclear myopathies (CNMs) by reducing the expression of a single protein, DNM2. CNMs are severe congenital rare muscle disorders that result in muscle hypotrophy and weakness, with no cure. CNMs frequently result from mutations in either BIN1, MTM1, or DNM2 genes, with DNM2 being a key GTPase that plays a pivotal role in muscle membrane interactions with MTM1 and BIN1. Previous studies indicate that reducing DNM2 transcript expression by half could correct CNM phenotypes regardless the genetic forms, paving the way for a broad-spectrum CNM-therapy. We evaluated CRISPR/Cas13X.1-mediated DNM2 transcript knockdown, as a therapeutic application in a unique naturally-occurring canine CNM model harboring the DNM2R465W/+ mutation, the most frequent pathogenic variant in patients. We show that in vivo intramuscular AAV-mediated CRISPR/Cas13X.1 injections, led to a reduction in DNM2 transcript and protein levels at one and two months post-treatment. Our results demonstrate the feasibility of CRISPR/Cas13-based therapy for CNM in a large animal model, paving the way for advancing this approach towards clinical trials.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The beneficial effect of chronic muscular exercise on muscle fragility is increased by Prox1 gene transfer in dystrophic mdx muscle 94%
- Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5 94%
- Control of Quiescence and Activation of Human Muscle Stem Cells by Cytokines 93%
Similar papers in this journal
- Integrated data from R405W desmin knock-in mice highlight alterations of mitochondrial function, protein quality control, and myofibrillar structure in the initial stages of myofibrillar myopathy 95%
- Cell autonomous requirement of Neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis 95%
- Numb is required for optimal contraction of skeletal muscle 95%
Similar papers in this journal
- Lamin-related congenital muscular dystrophy alters mechanical signaling and skeletal muscle growth 95%
- Muscle-specific DNM2 overexpression improves Charcot-Marie-Tooth disease in vivo and reveals a narrow therapeutic window in skeletal muscle 94%
- Postnatal protein intake as a determinant of skeletal muscle structure and function in mice - a pilot study 93%
Similar papers in this journal
- Complex feline disease mapping using a dense genotyping array 92%
- Screening and identification of muscle-specific candidate genes via mouse microarray data analysis 91%
- Temporal Extracellular Vesicle Protein Changes following Intraarticular Treatment with Integrin α10β1-selected Mesenchymal Stem Cells in Equine Osteoarthritis 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.